Monika Fischer

机构：Indiana University Health, Indiana University School of Medicine, Indiana University – Purdue University Indianapolis, Indiana University · ORCID：0000-0001-7162-6172

发表论文 293 篇 · 总被引 8909 次 · h-index 48

代表论文

• Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study (2024 · The Lancet · 被引 107)
• International consensus statement on microbiome testing in clinical practice (2024 · ˜The œLancet. Gastroenterology & hepatology · 被引 86)
• Endoscopic diagnosis and management of adult inflammatory bowel disease: a consensus document from the American Society for Gastrointestinal Endoscopy IBD Endoscopy Consensus Panel (2024 · Gastrointestinal Endoscopy · 被引 42)
• Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled Trial (2024 · Gastroenterology · 被引 19)
• Preferred Reporting Items for Microbiotherapy (PRIM) Guidelines Across Medical Disciplines: An International Delphi Consensus (2025 · Journal of Gastroenterology and Hepatology · 被引 18)
• Safety and Efficacy of Fecal Microbiota, Live-jslm, in Preventing Recurrent Clostridioides difficile Infection in Participants Who Were Mildly to Moderately Immunocompromised in the Phase 3 PUNCH CD3-OLS Study (2025 · Open Forum Infectious Diseases · 被引 8)